Silverback Therapeutics/SPRY

$8.82

0.8%
-
1D1W1MYTD1YMAX

About Silverback Therapeutics

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy (also referred to as ARS-1), an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions, including food, medications, and insect bites that could lead to anaphylaxis. The Company has designed and developed neffy to provide injection-like absorption of epinephrine, at a low dose, easy-to-use small nasal spray device.

Ticker

SPRY

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Richard Lowenthal

Employees

24

Headquarters

San diego, United States

SPRY Metrics

BasicAdvanced
$801.58M
Market cap
1300.62
P/E ratio
$0.01
EPS
-
Beta
-
Dividend rate

What the Analysts think about SPRY

Analyst Ratings

Majority rating from 3 analysts.
Hold

Price Targets

Average projection from 2 analysts.
30.39% upside
High $19.00
Low $4.00
$8.82
Current price
$11.50
Average price target

SPRY Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-14.8M
-14.45%
Profit margin
0%
-

SPRY Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 12.41%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
$0.77
-$0.16
-$0.18
-$0.16
-
Expected
-$0.13
-$0.17
-$0.17
-$0.18
-$0.14
Surprise
-692.31%
-4.57%
3.65%
-12.41%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Silverback Therapeutics stock

Buy or sell Silverback Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing